The expression of ICOS (Figure 5D), TNFSF14 (Figure 5E), and ULBP1 (Figure 5F) was assessed by immunohistochemistry in patients with glioma, confirming that TNFSF14 was associated with the clinical outcome of patients with glioma (Figure 5G). Here, ULBP1 is linked to glioma.